Physician profile
Bret Hafen
NPI 1982060828
$380,936.48
in general payments reported to CMS, 2019-2025
22 companies · $218K in 2025
The $218K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,429 · 2022: $1,927 · 2023: $43K · 2024: $117K · 2025: $218K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $291K · Travel and Lodging: $52K · Food and Beverage: $19K · Consulting Fee: $16K · Education: $42.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $290,644.25 |
| Travel and Lodging | $51,843.33 |
| Food and Beverage | $19,125.85 |
| Consulting Fee | $15,925.00 |
| Education | $42.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $203,258.05 | 2021-2025 | Caplyta |
| Abbvie INC. | $76,288.46 | 2021-2025 | |
| Alkermes, INC. | $37,509.28 | 2022-2025 | Lybalvi, Vivitrol, Aristada |
| Janssen Pharmaceuticals, INC | $30,068.64 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $20,506.37 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $7,731.77 | 2024-2025 | Cobenfy |
| Janssen Scientific Affairs, LLC | $1,755.58 | 2023-2025 | Invega Trinza, Invega Sustenna, Invega |
| Sunovion Pharmaceuticals INC. | $1,207.33 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $577.74 | 2021-2024 | Fanapt, Hetlioz |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $404.80 | 2023-2025 | Abilify Asimtufii, Rejoyn, Abilify Maintena |
| Neurocrine Biosciences, INC. | $332.84 | 2023-2025 | Ingrezza |
| Indivior INC. | $317.71 | 2021-2024 | Sublocade, Perseris |
| Lundbeck LLC | $232.22 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $205.60 | 2023 | Auvelity |
| Braeburn INC. | $196.40 | 2023-2024 | Brixadi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $82.09 | 2022-2024 | Austedo Xr |
| Neuronetics, INC. | $80.12 | 2024-2025 | Neurostar Tms Therapy System |
| Eisai INC. | $64.60 | 2021 | |
| Ironshore Pharmaceuticals INC. | $39.86 | 2023-2024 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $31.39 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $30.58 | 2023 | Latuda |
| Noven Therapeutics, LLC | $15.05 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bret Hafen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.